Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Implantation and Analysis of a Biphasic Bioinspired Osteochondral Chitosan Construct in a Large Animal Model.

ACS biomaterials science & engineering·2026
Same author

Analysis of Primary Cilium-Bearing Human Neuroprogenitors Using Flow Cytometry.

Stem cells international·2026
Same author

Antitumor Effects of Chemlali and Wild Olive Tree Extracts: Role in Cell Proliferation and Apoptosis in Prostate (PC3) and Breast (MDA-MB-231) Cancer Cell Lines.

BioMed research international·2025
Same author

<i>In vitro</i>degradation of a chitosan-based osteochondral construct points to a transient effect on cellular viability.

Biomedical materials (Bristol, England)·2024
Same author

Joubert syndrome-derived induced pluripotent stem cells show altered neuronal differentiation in vitro.

Cell and tissue research·2024
Same author

Patient-derived cellular models of primary ciliopathies.

Journal of medical genetics·2022

Related Experiment Video

Updated: Jun 18, 2026

Pre-Conditioning the Airways of Mice with Bleomycin Increases the Efficiency of Orthotopic Lung Cancer Cell Engraftment
09:02

Pre-Conditioning the Airways of Mice with Bleomycin Increases the Efficiency of Orthotopic Lung Cancer Cell Engraftment

Published on: June 28, 2018

14.2K

Differentiation Treatment Applied to Lung Cancer Model Reduces Pathogenic Traits in Vitro.

Grossi Alice1, Fulghieri Paola1, Aduvaliev Abdurakhmon1

  • 1Department of Molecular Medicine, University of Pavia, Pavia, Italy.

Advanced Biology
|November 30, 2025
PubMed
Summary

Pro-differentiation factors reduced the aggressiveness of non-small cell lung cancer (NSCLC) cells. This approach decreased proliferation, migration, and stemness markers, suggesting a potential new therapy for NSCLC.

Keywords:
differentiationinhibitionlung adenocarcinoma modelmigrationstem cell markers

More Related Videos

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

18.0K
A Minimally Invasive Method for Generating a Syngeneic Orthotopic Mouse Model of Lung Cancer
07:46

A Minimally Invasive Method for Generating a Syngeneic Orthotopic Mouse Model of Lung Cancer

Published on: August 19, 2025

992

Related Experiment Videos

Last Updated: Jun 18, 2026

Pre-Conditioning the Airways of Mice with Bleomycin Increases the Efficiency of Orthotopic Lung Cancer Cell Engraftment
09:02

Pre-Conditioning the Airways of Mice with Bleomycin Increases the Efficiency of Orthotopic Lung Cancer Cell Engraftment

Published on: June 28, 2018

14.2K
Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

18.0K
A Minimally Invasive Method for Generating a Syngeneic Orthotopic Mouse Model of Lung Cancer
07:46

A Minimally Invasive Method for Generating a Syngeneic Orthotopic Mouse Model of Lung Cancer

Published on: August 19, 2025

992

Area of Science:

  • Oncology
  • Cancer Stem Cell Biology
  • Cellular Differentiation

Background:

  • Relapse in non-small cell lung cancer (NSCLC) is often driven by aggressive, chemoresistant, and metastatic cancer stem cells (CSCs).
  • Pro-differentiation therapies have shown promise in other cancers, offering a potential strategy to target CSCs.

Purpose of the Study:

  • To investigate the effects of pro-differentiation factors (DM) on the biological properties and stemness of human NSCLC A549 cells.
  • To assess the potential of DM as an anti-cancer therapeutic strategy by evaluating its impact on CSC characteristics.

Main Methods:

  • A549 NSCLC cells were treated with serum-containing medium supplemented with pro-differentiation factors (DM).
  • In vitro assays were performed to assess changes in cell proliferation, migration, adhesion, and colony formation (2D and 3D cultures).
  • Expression of stemness markers (SOX2, NANOG, CD44, ABCG2), ALDH activity, and aquaporin function were analyzed post-treatment.

Main Results:

  • DM treatment induced significant morphological changes, reduced cell proliferation and migration, and increased cell adhesion.
  • A substantial decrease in clonogenic ability, anchorage-independent colony formation, and spheroid growth was observed.
  • DM exposure led to reduced expression of key stemness markers (SOX2, NANOG, CD44, ABCG2), decreased ALDH activity, and altered aquaporin function.

Conclusions:

  • Pro-differentiation factor treatment significantly reduced the pathogenic features of NSCLC A549 cells.
  • This approach effectively decreased cancer stem cell characteristics, suggesting its potential as a valuable therapeutic strategy for NSCLC.
  • Further preclinical testing of pro-differentiation therapy is warranted for NSCLC treatment.